Nyxoah Announces Closing of Underwritten Public Offering
Nyxoah SA said it has closed its previously announced underwritten U.S. public offering, selling 55,232,558 ordinary shares at $1.72 (EUR 1.48) each. Gross proceeds are about $95.0 million (EUR 81.9 million). Net proceeds will fund U.S. commercialization, Genio R&D and commercialization, and general corporate purposes; the company also plans to draw EUR 13.8 million from its EIB loan tranche in Q2 2026.
How this was made
The 30-second read
Why it matters
Closing the underwritten US offering provides cash for US commercialization, Genio system upgrades and manufacturability/cost reduction, and expansion outside the US, while introducing dilution from the newly issued shares.
Market read
A completed equity raise with explicit use-of-proceeds can shift near-term valuation via dilution expectations and improved funding visibility for commercialization and R&D.
What to watch
The article notes a planned EUR 13.8M draw from the EIB second tranche in Q2 2026; traders may reprice the combined funding runway rather than focusing only on dilution from the equity offering.
Background
Nyxoah is a medical technology company developing the Genio leadless, battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea (OSA).
Ticker impact
Nyxoah closed a US underwritten public offering selling 55,232,558 shares at $1.72 to raise ~$95.0M gross proceeds.
Near-term pressure from dilution is possible, partially offset by improved funding visibility for commercialization and R&D.
The article discloses offering size/price and stated use of proceeds, but provides no guidance or immediate operational milestones beyond planned commercialization and a planned EIB tranche draw.
Market effects
Adds incremental funding to a medical device/OSA commercialization story, which can influence sentiment toward small-cap medtech financing risk.
Primarily US capital markets impact for a dual-listed issuer; may affect Euronext/Nasdaq cross-venue liquidity and sentiment.
Limited beyond the company; proceeds also support EU/other-market expansion and clinical data generation.
Counterpoint
If the market had been discounting funding risk, the completed ~$95M raise could be viewed as de-risking execution and reducing the probability of future emergency dilution.
Key entities
- companyNyxoah SA
Medical technology company focused on OSA; closed a US underwritten public offering and plans to use net proceeds for commercialization and Genio R&D.
- bankBofA Securities
Lead bookrunner for the offering.
- lenderEuropean Investment Bank (EIB)
Company intends to draw EUR 13.8M from the second tranche in Q2 2026.
